DE602006009899D1 - Verwendung von oxycodon zur behandlung von viszeralem schmerz - Google Patents

Verwendung von oxycodon zur behandlung von viszeralem schmerz

Info

Publication number
DE602006009899D1
DE602006009899D1 DE602006009899T DE602006009899T DE602006009899D1 DE 602006009899 D1 DE602006009899 D1 DE 602006009899D1 DE 602006009899 T DE602006009899 T DE 602006009899T DE 602006009899 T DE602006009899 T DE 602006009899T DE 602006009899 D1 DE602006009899 D1 DE 602006009899D1
Authority
DE
Germany
Prior art keywords
oxycodone
treatment
visceral pain
visceral
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602006009899T
Other languages
German (de)
English (en)
Inventor
Asbjorn Mohr Drewes
Lars Arendt Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602006009899(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of DE602006009899D1 publication Critical patent/DE602006009899D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
DE602006009899T 2005-01-18 2006-01-17 Verwendung von oxycodon zur behandlung von viszeralem schmerz Expired - Lifetime DE602006009899D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
PCT/EP2006/050252 WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Publications (1)

Publication Number Publication Date
DE602006009899D1 true DE602006009899D1 (de) 2009-12-03

Family

ID=35871217

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602006009899T Expired - Lifetime DE602006009899D1 (de) 2005-01-18 2006-01-17 Verwendung von oxycodon zur behandlung von viszeralem schmerz
DE202006019887U Expired - Lifetime DE202006019887U1 (de) 2005-01-18 2006-01-17 Medikament zur Behandlung von viszeralem Schmerz

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE202006019887U Expired - Lifetime DE202006019887U1 (de) 2005-01-18 2006-01-17 Medikament zur Behandlung von viszeralem Schmerz

Country Status (31)

Country Link
US (2) US20080200493A1 (https=)
EP (1) EP1838318B1 (https=)
JP (1) JP5049139B2 (https=)
KR (10) KR20230170811A (https=)
CN (1) CN101106996B (https=)
AP (1) AP2249A (https=)
AR (1) AR052880A1 (https=)
AT (2) ATE446092T1 (https=)
AU (1) AU2006207498B2 (https=)
BR (1) BRPI0606247A2 (https=)
CA (1) CA2595043C (https=)
CY (1) CY1109660T1 (https=)
DE (2) DE602006009899D1 (https=)
DK (2) DK1838318T3 (https=)
EA (1) EA013544B1 (https=)
ES (1) ES2333901T3 (https=)
HR (1) HRP20090679T1 (https=)
IL (1) IL184530A (https=)
ME (1) ME01066B (https=)
MX (1) MX2007007207A (https=)
MY (1) MY144471A (https=)
NO (1) NO338968B1 (https=)
NZ (1) NZ555852A (https=)
PL (1) PL1838318T3 (https=)
PT (1) PT1838318E (https=)
RS (1) RS51069B (https=)
SI (1) SI1838318T1 (https=)
TW (1) TWI432196B (https=)
UA (1) UA85471C2 (https=)
WO (1) WO2006077212A1 (https=)
ZA (1) ZA200705231B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3069731A1 (en) 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
RU2522493C2 (ru) 2008-03-04 2014-07-20 Пфайзер Лимитед Способы лечения хронической боли
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
CN102740884A (zh) 2009-08-28 2012-10-17 瑞纳神经科学公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
PE20141787A1 (es) 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
TWI705825B (zh) 2011-05-20 2020-10-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）或抗降血鈣素基因相關胜肽受器（ａｎｔｉ－ｃｇｒｐ－ｒ）抗體或抗體片段治療或預防慢性及急性型腹瀉之用途
CN107827982B (zh) 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AU2015230933B2 (en) 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
WO2020146527A1 (en) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies
CA3077973A1 (en) 2020-04-06 2021-10-06 H. Lundbeck A/S Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
UA48219C2 (uk) * 1996-03-25 2002-08-15 Елі Ліллі Енд Компані Композиція для вгамування болю (варіанти) та спосіб вгамування болю
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
CA2595043A1 (en) 2006-07-27
PT1838318E (pt) 2009-12-15
KR20120089710A (ko) 2012-08-13
MY144471A (en) 2011-09-30
KR20070100368A (ko) 2007-10-10
KR20140091782A (ko) 2014-07-22
AU2006207498B2 (en) 2009-11-19
DE202006019887U1 (de) 2007-07-26
ES2333901T3 (es) 2010-03-02
IL184530A (en) 2015-01-29
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
US20150190393A1 (en) 2015-07-09
KR20200128451A (ko) 2020-11-12
NZ555852A (en) 2010-01-29
ATE446092T1 (de) 2009-11-15
CY1109660T1 (el) 2014-08-13
PL1838318T3 (pl) 2010-03-31
SI1838318T1 (sl) 2010-02-26
AU2006207498A1 (en) 2006-07-27
EA200701541A1 (ru) 2008-02-28
KR20190135557A (ko) 2019-12-06
KR20220165797A (ko) 2022-12-15
EP1838318B1 (en) 2009-10-21
AP2249A (en) 2011-07-18
DK200700207U3 (da) 2007-09-28
IL184530A0 (en) 2007-10-31
NO20074174L (no) 2007-10-17
AP2007004057A0 (en) 2007-08-31
JP5049139B2 (ja) 2012-10-17
KR20080106991A (ko) 2008-12-09
US20080200493A1 (en) 2008-08-21
EP1838318A1 (en) 2007-10-03
BRPI0606247A2 (pt) 2009-06-09
DK1838318T3 (da) 2010-01-04
AT9895U1 (de) 2008-05-15
AR052880A1 (es) 2007-04-11
ZA200705231B (en) 2008-06-25
WO2006077212A1 (en) 2006-07-27
DK200700207U1 (da) 2007-08-24
JP2008526927A (ja) 2008-07-24
KR20210131450A (ko) 2021-11-02
HRP20090679T1 (hr) 2010-01-31
CA2595043C (en) 2013-11-19
TW200637554A (en) 2006-11-01
KR20230170811A (ko) 2023-12-19
HK1107933A1 (en) 2008-04-25
CN101106996B (zh) 2013-10-23
NO338968B1 (no) 2016-11-07
RS51069B (sr) 2010-10-31
UA85471C2 (ru) 2009-01-26
CN101106996A (zh) 2008-01-16
ME01066B (me) 2012-10-20
US9271974B2 (en) 2016-03-01
EA013544B1 (ru) 2010-06-30
TWI432196B (zh) 2014-04-01

Similar Documents

Publication Publication Date Title
ATE399155T1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
EP1755661A4 (en) USE OF GELSOLINE FOR THE TREATMENT OF INFECTIONS
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
ZA200705231B (en) Use of oxycodone for treating visceral pain
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
DE60313021D1 (de) 4-tetrazolyl-4-phenylpiperidindervate zur schmerzbehandlung
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
DE602004019576D1 (de) Zur behandlung von schmerzen geeignete piperazine
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602005027251D1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
EP2403501A4 (en) PREENGENOLONE SULFATE FOR THE TREATMENT OF NEUROLOGICAL DISEASES
DE602005013287D1 (de) Zusammensetzung zur behandlung von leder
DE602005015442D1 (de) Kollagen-polyvinylpyrrolidon zur behandlung von osteoarthritis
DE502005002104D1 (de) Hesperidin zur Behandlung von Epilepsie
DE602004003252D1 (de) Verwendung von 2h-ä1,3ü-oxazinoä3,2-aüindol-derivaten zur behandlung von neuropathischem schmerz

Legal Events

Date Code Title Description
8363 Opposition against the patent